{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:51:28Z","timestamp":1791654688110,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.tips.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:15:30Z","timestamp":1642407330000},"page":"266-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is the AT-rich DNA of malaria parasites a drug target?"],"prefix":"10.1016","volume":"43","author":[{"given":"Michaela S.","family":"Bulloch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-7808","authenticated-orcid":false,"given":"Stuart A.","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2022.01.003_bb0005","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite Plasmodium falciparum","volume":"419","author":"Gardner","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.tips.2022.01.003_bb0010","first-page":"1889","article-title":"Extreme mutation bias and high AT content in Plasmodium falciparum","volume":"45","author":"Hamilton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2022.01.003_bb0015","article-title":"A non-reactive natural product precursor of the duocarmycin family has potent and selective antimalarial activity","author":"Alder","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tips.2022.01.003_bb0020","first-page":"1331","article-title":"Isolation and characterization of PDE-I and II, the inhibitors of cyclic adenosine-3\u2032,5\u2032-monophosphate phosphodiesterase","volume":"42","author":"Enomoto","year":"1978","journal-title":"Agric. Biol. Chem."},{"key":"10.1016\/j.tips.2022.01.003_bb0025","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1073\/pnas.92.9.3642","article-title":"CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents","volume":"92","author":"Boger","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2022.01.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015931","article-title":"Understanding the sequence-dependence of DNA groove dimensions: implications for DNA interactions","volume":"5","author":"Oguey","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2022.01.003_bb0035","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1006\/jmbi.2000.3887","article-title":"The structural basis for in situ activation of DNA alkylation by duocarmycin SA","volume":"300","author":"Smith","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2022.01.003_bb0040","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bmcl.2018.03.016","article-title":"Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA","volume":"28","author":"Kiakos","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2022.01.003_bb0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molbiopara.2007.04.009","article-title":"Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs","volume":"154","author":"Woynarowski","year":"2007","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.tips.2022.01.003_bb0050","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1073\/pnas.0409455102","article-title":"How sequence defines structure: a crystallographic map of DNA structure and conformation","volume":"102","author":"Hays","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614722000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614722000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:13:00Z","timestamp":1759050780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614722000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0165614722000049"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2022.01.003","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is the AT-rich DNA of malaria parasites a drug target?","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}